van Morris, MD
Hematology-Oncology · Durham, NCNPI 1134396534
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,566 of the $60,428 with a category attached, or 85.3%. 15 manufacturers reported payments, led by Incyte Corporation at 27.2% of the total. 2025 is the largest year on record at $29,846, more than ten times the $234 reported in 2019.
Across 74 payments — averaging $816.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$16K
- E.r. Squibb & Sons, L.L.C.$9K
- Novartis$6K
- Biontech SE$6K
- Regeneron$6K
- GSK$4K
- plus $13K from 9 others
Across 253 payments — averaging $29,672 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.8M
- Pfizer$2.8M
- Array Biopharma Inc$1M
- E.r. Squibb & Sons, L.L.C.$344K
- Biontech SE$260K
- Sumitomo Pharma America, Inc.$116K
- plus $203K from 5 others
What the payments were for
- Consulting fees$51,56685%
- Speaking & faculty fees$1,6503%
- Travel & lodging$4,2947%
- Food & beverage$2,9185%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 17 | $16,409 |
| E.r. Squibb & Sons, L.L.C. | 9 | $9,047 |
| Novartis | 3 | $6,486 |
| Biontech SE | 8 | $5,746 |
| Regeneron | 7 | $5,551 |
| GSK | 7 | $4,353 |
| Pfizer | 4 | $4,167 |
| AbbVie | 3 | $2,791 |
| Bayer | 6 | $2,384 |
| Exelixis Inc. | 2 | $1,825 |
| Boehringer Ingelheim International GmbH | 1 | $1,200 |
| Genentech USA, Inc. | 4 | $348 |
| Immunitybio, Inc. | 1 | $83 |
| Array Biopharma Inc | 1 | $25 |
| Genentech, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $204,905 |
| LoperamideLoperamide Hcl | 14 | $426 |
| Prochlorperazine Maleate | 16 | $299 |
| Ondansetron Hcl | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Other hematology-oncology in Durham
- Cristiana ChaseDurham$133K
- Louis DiehlDurham$0
- Jonathan SorahChapel Hill$5K
- Mark WoodcockChapel Hill$123
- Micah MooberryChapel Hill$0
- Lee BerkowitzChapel Hill$0
- Jeremy MeierChapel Hill$0
- Fatima AliMonroe$0
- Danyu SunCharlotte$0
- Sridhar PalCharlotte$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.